Listed

Kiora Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2016

Filed with the SEC on Feb 23, 2017 and accepted by EDGAR at Feb 23, 2017, 16:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2016-01-01 to 2016-12-31$669.3kus-gaap:SalesRevenueNet
Research and development12 months2016-01-01 to 2016-12-31$8.4mus-gaap:ResearchAndDevelopmentExpense
Interest expense12 months2016-01-01 to 2016-12-31$275us-gaap:InterestExpense
Net income12 months2016-01-01 to 2016-12-31−$13.3mus-gaap:ProfitLoss
Diluted EPS12 months2016-01-01 to 2016-12-31−$1.51us-gaap:EarningsPerShareBasicAndDiluted
Cash and equivalentsAt period end2016-12-31$3.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-12-31$4.2mus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$9.7mus-gaap:Assets
Current liabilitiesAt period end2016-12-31$7.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-12-31$10.1mus-gaap:Liabilities
Shareholders' equityAt period end2016-12-31−$329.4kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-010635. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.